Category Archives: LDK378 – Ceritinib from Novartis

Crizotinib / Ceritinib mutation study

Below is a link to a Cancer Discovery article, which found that biopsies of patients with crizotinib-resistant NSCLC, revealed that ceritinib potently overcomes crizotinib-resistant mutations. In particular, ceritinib effectively inhibits ALK harboring L1196M, G1269A, I1171T, and S1206Y mutations. However, they … Continue reading

Posted in Crizotinib - Xalkori from Pfizer, LDK378 - Ceritinib from Novartis, Research, Resistance to treatment | Leave a comment

Comparing new ALK inhibitors

Here is a video on cancergrace.org by Dr. Leena Gandhi of Dana-Farber talking about various new ALK inhibitors compared with Crizotinib. The video is sponsored by Genentech which is a sister company to Chugai, which created Alectinib, so some of … Continue reading

Posted in AP26113 from Ariad, Brain metastases, CH542802 - Alectinib from Chugai - Roche, Crizotinib - Xalkori from Pfizer, LDK378 - Ceritinib from Novartis, Lung cancer, Potential Treatments, Side Effects | Leave a comment

Abstracts from upcoming ASCO conference

Overall, I would say the results were disappointing, fewer patients had progressed far enough for meaningful results than I had hoped for. However, given that the data cut offs were usually around December and most of the trials were near … Continue reading

Posted in AP26113 from Ariad, Brain metastases, CH542802 - Alectinib from Chugai - Roche, LDK378 - Ceritinib from Novartis, RXDX-101 by Ignyta, TSR-011 from Tesaro, X-396 from Xcovrery | Leave a comment

List of 9 ALK Inhibitors

List of 9 ALK inhibitor drugs currently in clinical trials: FDA approved (but several trials ongoing) Novartis – Ceritinib Pfizer – Crizotinib FDA Breakthrough Status Chugai – Alectinib (filed NDA in Japan) Ongoing trials Ariad AP26113 Nerviano NMS-E628. (Licensed by … Continue reading

Posted in AP26113 from Ariad, CEP-37440, CH542802 - Alectinib from Chugai - Roche, Crizotinib - Xalkori from Pfizer, LDK378 - Ceritinib from Novartis, Lung cancer, NMS-E628, Potential Treatments, Regulatory applications & approvals, Research, RXDX-101 by Ignyta, TSR-011 from Tesaro, X-396 from Xcovrery | Leave a comment

FDA approves LDK378 (Ceritinib).

Novartis gains FDA approval for Zykadia(TM). Breakthrough therapy drug approved four months ahead of review completion goal date. http://www.novartis.com/newsroom/media-releases/en/2014/1776962.shtml http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm395299.htm For an interesting commentary see: http://cancergrace.org/lung/2014/04/30/new-approval-for-zykadia-ldk378ceritinib-in-alk-positive-nsclc-why-it-matters-even-if-youre-not-alk-positive/#more-14473

Posted in Brain metastases, LDK378 - Ceritinib from Novartis, Lung cancer, Potential Treatments, Regulatory applications & approvals, Resistance to treatment, Side Effects | Leave a comment

ESMO – Next Generation ALK Inhibitors

Here is a summary of a presentation on next generation ALK inhibitors. ESMO Presentation

Posted in AP26113 from Ariad, CH542802 - Alectinib from Chugai - Roche, LDK378 - Ceritinib from Novartis, Lung cancer, Potential Treatments, Regulatory applications & approvals, Research, Resistance to treatment, Side Effects | Leave a comment

Grace has posted videos from the Santa Monica ALK patient forum

CancerGrace.org has posted nine videos from a February 24, 2014 patient forum. There were four doctors doing research on ALK+ Lung Cancer who discussed topics and answered questions. They included Dr. Alice Shaw, Dr. Ross Camidge, Dr. Jared Weiss, and … Continue reading

Posted in AP26113 from Ariad, Brain metastases, CH542802 - Alectinib from Chugai - Roche, Crizotinib - Xalkori from Pfizer, Experiences, LDK378 - Ceritinib from Novartis, Lung cancer, Potential Treatments, Research, Resistance to treatment, Side Effects | Leave a comment

LDK378 (Ceritinib) Study Published in NEJM

A couple of people have kindly pointed out that I have been reading these medical studies for too long and I am starting to sound like them. For short summary see bottom of post. So here is an attempt to … Continue reading

Posted in Brain metastases, LDK378 - Ceritinib from Novartis, Lung cancer, Potential Treatments, Regulatory applications & approvals, Research, Resistance to treatment, Side Effects | Leave a comment

Video on 2nd generation ALK Inhibitors

Here is a 7 minute video of several doctors discussing second generation ALK inhibitors. http://www.onclive.com/peer-exchange/nsclc-outcomes/Second-Generation-ALK-Inhibitors-in-NSCLC

Posted in AP26113 from Ariad, Brain metastases, LDK378 - Ceritinib from Novartis, Lung cancer, Potential Treatments, Research, Resistance to treatment, Side Effects | Leave a comment

Treatment options for a few brain mets while on Crizotinib

Here is a good discussion on Grace of various treatment options (LDK378, WBR, and gama/cyber knife) for a patient on Xalkori (Crizotinib) who develops a few brain mets. I found interesting the changing perspectives of doctors about WBR side effects … Continue reading

Posted in Brain metastases, Crizotinib - Xalkori from Pfizer, LDK378 - Ceritinib from Novartis, Lung cancer, Potential Treatments | Leave a comment